Last Updated : March 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Pending | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Pending | |||
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Pending | |||
N/A | nab-paclitaxel | Gastrointestinal cancer | Pending | |||
Alecensaro | alectinib | ALK-positive NSCLC | Pending | |||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Pending | |||
TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Pending | |||
Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | |||
Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn | |||
Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active |